ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SCTX / financials
EIKN (43) SABS (38) AGEN (29) IPSC (18) ⌘ Pro Terminal →

Scribe Therapeutics Inc. (SCTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$15.54 +0.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.53

Scribe Therapeutics Inc. (SCTX) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $291.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SCTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Scribe Therapeutics Inc. (NASDAQ: SCTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $15.54 (+0.78% 1D, market cap $291.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, SCTX ranks #408 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SCTX compare to EIKN and SABS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCTX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EIKN (Eikon Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $287.6M) and SABS (SAB Biotherapeutics Inc.) posts a D- grade (38/100 RQD, P/E 22.1x, ROIC -27.4%, cap $304.8M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while IPSC leads on capital efficiency (-14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SCTX?
▼

Per SCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001853921), Scribe Therapeutics Inc. generated $32.9M in revenue, $0 in net income, and $0 in free cash flow against $78.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $15.53 (-0.05%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 24.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510043
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (10)Whales (3)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.8% Base Target
$42 Bull$14 Base$11 Bear
📬 FREE SCTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SCTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY SCTX SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 24.9% FCF Margin ($8.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
51
Grade C-$19.12+3.6% Next Q
Q2 (-2Q)
48
Grade D$19.81-19.4% Next Q
Q3 (-1Q)
46
Grade D$15.96-2.6% Next Q
Current
43
Grade D-$15.54-6.7% Hist 90D α
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SCTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SCTX currently carries a cautious 43/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.33) and Max Pain ($16.32) forces dealer call-delta covering toward $41.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SCTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SCTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SCTX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$8.2M (24.9% FCF Margin)
Revenue$32.9MGross Profit $17.1M (52%)Cost of Sales $15.8MOp Profit $0 (0%)OpEx (R&D/SG&A) $17.1MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY25
Rev $32.9M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$32.9M52%0%$0$015%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCTX)

  • ✓Walkthrough of SCTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SCTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.08%▼ DESCENDING CHANNEL
2026-11-03O $17.44H $17.44L $15.42C $15.54VOL 480.7K
RES: $28.68SUP: $10.15SMA50: $23.33SMA200: $23.61
$41.43$33.86$26.29$18.72$11.15RES $28.68SUP $10.15$15.542026-07-272026-08-192026-09-152026-10-082026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SCTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SCTX Butterfly Map → + Track SCTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SCTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SCTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SCTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCTX)

Health Care Rank #408 of 1015 ⚔️ EIKN vs SCTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SCTX vs. EIKN, SABS, AGEN, IPSC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Scribe Therapeutics Inc. (SCTX) ranks #408 by composite RQD confidence (43/100, grade D-) and #519 by equity capitalization ($291.9M). Within this direct 5-issuer industry benchmark cohort, SABS leads on earnings valuation at 22.1x trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. SCTX currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SCTX ACTIVE
Scribe Therapeutics Inc.
D- 43/100 — — — +0.78% $291.9M Benchmark Subject
EIKN
Eikon Therapeutics Inc.
D- 43/100 — — — +6.97% $287.6M /eikn-vs-sctx →
SABS
SAB Biotherapeutics Inc.
D- 38/100 22.1x — -27.4% -1.49% $304.8M /sabs-vs-sctx →
AGEN
Agenus Inc.
E 29/100 — 96.0% -35.0% -4.53% $308.9M /agen-vs-sctx →
IPSC
Century Therapeutics Inc.
E 18/100 — — -14.1% +0.68% $266.2M /ipsc-vs-sctx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001853921 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scribe Therapeutics Inc. (SCTX) reported GAAP revenue of $32.9M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, SCTX closed FY2025 with $78.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $32.9M $0 — — $78.2M —

3. SCTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Scribe Therapeutics Inc. (NASDAQ: SCTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $15.54 (+0.78% 1D, market cap $291.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, SCTX ranks #408 in composite RQD confidence.

How does SCTX compare to EIKN and SABS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCTX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EIKN (Eikon Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $287.6M) and SABS (SAB Biotherapeutics Inc.) posts a D- grade (38/100 RQD, P/E 22.1x, ROIC -27.4%, cap $304.8M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SCTX?

Per SCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001853921), Scribe Therapeutics Inc. generated $32.9M in revenue, $0 in net income, and $0 in free cash flow against $78.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SCTX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCTX last traded at $15.54 (+0.78% on volume of 332,128 shares), positioning the stock -33.39% below its 50-day simple moving average ($23.33) and -34.18% below its 200-day simple moving average ($23.61). Across its 52-week range of $13.50 to $39.60, SCTX sits at the 7.8% percentile with a 14-day RSI of 39.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.60 to $17.48).

Direct Sub-Reports: SCTX RQD Cockpit SCTX 12M Forecast SCTX Earnings & Move SCTX Dividends & DRIP SCTX Insiders & 13F SCTX Whale Options SCTX Profit Sankey SCTX News & Why
ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ SEC XBRL & RQD VERIFIED

SCTX — Scribe Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Scribe Therapeutics Inc. (SCTX) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $15.54 (+0.78% 1D, market capitalization $291.9M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Scribe Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..3B by market capitalization. — describes its specific products, customers, or revenue model. The source data reports — in revenue for FY 2025, so the business model cannot be characterized from the financials provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Scribe Therapeutics Inc. (SCTX) reported $32.9M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $78.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 43/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $13.50 – $39.60 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE, with no upstream or downstream links and no proprietary signals recorded. — identifies upstream suppliers, downstream customers, or sector correlations beyond the Health Care sector and biotechnology industry classification. A prospective investor should note that the absence of mapped dependencies means second-order bottlenecks cannot be assessed from the provided material. The beta of 1.0 indicates the stock is, per the market data, expected to move in line with the broader market, but sector-specific ripples are not quantified in source data.

  • Key Question #1: Can SCTX sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $32.9M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SCTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SCTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Scribe Therapeutics Inc. (SCTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SCTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SCTX Bull vs. Bear Conversation Board — What's Your Call at $15.54?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SCTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SCTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $19.58 (+27.0%)
📌 Pinned Debate

Forensic balance sheet scores 13/20 with Altman Z 2.5 and Piotroski F 6/9, and the news wire flags a near-term catalyst and rising shor

Forensic balance sheet scores 13/20 with Altman Z 2.5 and Piotroski F 6/9, and the news wire flags a near-term catalyst and rising short interest.. When you look under the hood at SCTX, Fundamental Cash Engine is 10/20 with 0.0% gross margins and 0.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $39.60. My 12M target is $19.58.

VolSurface_Trader 🐂 BULL

@BearTrap_Alert Shorting a 3/20 institutional whale-flow stock at $15.42 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $12.34 (-20.0%)
Spot @ $15.42

Zero ROIC, zero FCF yield, zero revenue, and institutional flow scoring only 3/20 leave no reported cash engine supporting the $17.44 p

Fading this rally in SCTX at $15.42. Zero ROIC, zero FCF yield, zero revenue, and institutional flow scoring only 3/20 leave no reported cash engine supporting the $17.44 price.. With a beta of 1.0 and the stock sitting at $15.42 (52-wk range $13.50–$39.60), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%